No Data
No Data
Roche (RHHBY.US) has received approval for Roctavian in China for the treatment of relapsing and primary progressive multiple sclerosis.
Roche Pharmaceuticals (RHHBY.US) announced that its Innovative Drug Ocrevus (generic name: ocrelizumab injection) has officially been approved by the National Medical Products Administration of China.
Trump's Medical Tariffs Could Significantly Hurt These European Healthcare Firms
ROCHE HOLDING AG To Go Ex-Dividend On March 28th, 2025 With 1.36297 USD Dividend Per Share
Marty Makary and Jay Bhattacharya Clear Senate Hurdles to Lead FDA and NIH
AlphaValue/Baader Europe Raises Roche Price Target on 'Healthy' Growth Prospects
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)